是否应停止对M2闭塞的血管内治疗?对近期证据的批判性审视
本文综述了近期三项随机试验(ESCAPE-MeVO、DISTAL、DISCOUNT)未显示血管内取栓在远端和中等血管闭塞中带来临床获益的结果,并指出这些结果可能使临床医生对M2闭塞的取栓治疗产生犹豫。文章批判性分析了当前文献,重点关注M2段的解剖和功能定义及其分类的显著异质性,并强调了近端和优势M2分支的现有证据。
要点
- 近期三项随机试验未显示血管内取栓在远端和中等血管闭塞中的临床获益。
- M2段的解剖和功能定义存在显著异质性,可能影响试验结果解读。
- 近端和优势M2分支的现有证据(包括观察性研究、荟萃分析和既往随机试验)提示可能获益。
核心结论
- 近期中性试验的方法学局限和患者选择偏倚可能限制其广泛适用性,不应据此完全停止对M2闭塞的血管内治疗。
研究设计与样本
- 本文为综述,批判性审视当前文献,重点关注M2段的解剖和功能定义、分类异质性,以及近端和优势M2分支的现有证据。
主要发现
- ESCAPE-MeVO、DISTAL和DISCOUNT试验未显示血管内取栓在远端和中等血管闭塞中的临床获益。
- M2段的解剖和功能定义存在显著异质性,可能影响临床试验结果的解读。
- 既往证据(包括观察性研究、荟萃分析和先前随机试验)提示M2闭塞亚组可能从血管内取栓中获益。
临床怎么用
- 临床医生在面对M2闭塞时,应综合考虑近端或优势M2分支的解剖特征及现有证据,而非仅依据近期中性试验结果一概否定取栓治疗。
局限性
- 近期中性试验存在方法学局限和患者选择偏倚,可能影响其结论的普遍性。
- M2闭塞分类系统不统一,导致研究间可比性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Medium vessel occlusions represent a substantial proportion of patients with acute ischemic stroke. Recently presented randomized controlled trials, ESCAPE-MeVO (Endovascular Treatment to Improve Outcomes for Medium Vessel Occlusions), DISTAL (Endovascular Therapy Plus Best Medical Treatment [BMT] Versus BMT Alone for Medium Distal Vessel Occlusion Stroke), and DISCOUNT (Evaluation of Mechanical Thrombectomy in Acute Ischemic Stroke Related to a Distal Arterial Occlusion), did not demonstrate a clinical benefit of endovascular thrombectomy in distal and medium vessel occlusions, potentially generating uncertainty about optimal treatment strategies for medium vessel occlusions. Specifically, these results may lead clinicians to hesitate in performing endovascular thrombectomy for M2 occlusions, despite prior evidence indicating benefit in this subgroup. In this review, we critically examine current literature, focusing on anatomic and functional definitions of M2 segments, and highlight the significant heterogeneity in their classification. We place a particular emphasis on proximal as well as dominant M2 branches and the existing evidence, including observational studies, meta-analyses, and prior randomized trials. Additionally, we discuss methodological limitations and patient-selection biases of recent neutral trials, which may warrant caution in the broad application of their findings. Lastly, we propose recommendations for future research, emphasizing the need for refined patient-selection criteria to better identify subgroups most likely to benefit from endovascular thrombectomy, improved classification systems for M2 occlusions, and the exploration of adjunctive and alternative therapies.
引用
- Mehta A, Goldman D, Raz E, et al. Should We Stop Endovascular Treatment of M2 Occlusions?: A Critical Look at Recent Evidence. Stroke. 2025. PMID: 40854043. doi:10.1161/STROKEAHA.125.051578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。